{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:11:56Z","timestamp":1785190316334,"version":"3.55.0"},"reference-count":143,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The incidence of metabolic-associated steatotic liver disease (MASLD) remains persistently high, and there is a lack of specific therapeutic drugs in clinical practice. Elucidating the mechanistic pathways of therapeutic drugs for MASLD and exploring biomarkers with high specificity and sensitivity are of great significance for the precise diagnosis and treatment of the disease. The present study aims to review the research progress in this relevant field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically collated recent domestic and international literature on the mechanistic pathways of therapeutic drugs and biomarkers for MASLD, and analyzed the mechanisms of action, key signaling pathways of different therapeutic drugs, as well as the characteristics of various biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Drugs for MASLD treatment mainly exert their effects by regulating lipid metabolism, ameliorating insulin resistance (IR), and inhibiting inflammation and oxidative stress. For instance, peroxisome proliferator-activated receptors (PPARs) agonists improve lipid metabolism and IR via the PPARs signaling pathway; adenosine monophosphate-activated protein kinase (AMPK) activators enhance insulin sensitivity through the AMPK signaling pathway; and anti-inflammatory drugs alleviate inflammatory injury by inhibiting the nuclear factor kappa-B (NF-\u03baB) signaling pathway. Relevant biomarkers include metabolomic biomarkers (lipidome, amino acidome, etc.), inflammatory biomarkers (tumor necrosis factor-\u03b1[TNF-\u03b1], interleukin-6 [IL-6], etc.), liver fibrosis biomarkers (procollagen type III [Pro-C3], enhanced liver fibrosis [ELF] score, etc.) and non-coding RNA biomarkers, each exhibiting distinct values in disease diagnosis and therapeutic efficacy evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>At present, the core mechanistic pathways of a variety of MASLD therapeutic drugs and potential biomarkers have been identified, yet problems such as insufficient targeting in drug research and development and difficulties in the clinical translation of biomarkers still exist. In the future, it is necessary to further deepen mechanistic research, promote the development of precision therapeutic drugs and the clinical application of biomarkers, so as to provide more reliable theoretical and practical support for the diagnosis and treatment of MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcell.2026.1808135","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:36:05Z","timestamp":1776922565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Lifen","family":"Xue","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Technology Development Center, Chongqing Medical and Pharmaceutical College","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Mao","sequence":"additional","affiliation":[{"name":"Technology Development Center, Chongqing Medical and Pharmaceutical College","place":["Chongqing, China"]},{"name":"Department of Science and Education, The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/j.gastro.2023.11.007","article-title":"Nonalcoholic fatty liver disease gets renamed as metabolic dysfunction\u2013associated steatotic liver disease: progress but with challenges","volume":"166","author":"Allen","year":"2024","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/0122115366359521250122115511","article-title":"MicroRNAs in metabolic dysfunction-associated steatotic liver disease: a systematic review of clinical studies","volume":"14","author":"Antoniou","year":"2025","journal-title":"MicroRNA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/hepr.14241","article-title":"Effect of tirzepatide treatment on hepatic biomarkers in patients with metabolic dysfunction\u2010associated steatotic liver disease and type 2 diabetes mellitus","volume":"55","author":"Arai","year":"2025","journal-title":"Hepatology Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102664","DOI":"10.1016\/j.cpcardiol.2024.102664","article-title":"Pharmacovigilance study for SGLT 2 inhibitors- safety review of real-world data and randomized clinical trials","volume":"49","author":"Bhanushali","year":"2024","journal-title":"Curr. Problems Cardiology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta\u2010analysis: pioglitazone improves liver histology and fibrosis in patients with non\u2010alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"15708","DOI":"10.3390\/ijms232415708","article-title":"Plasma calprotectin levels associate with suspected metabolic-associated fatty liver disease and all-cause mortality in the general population","volume":"23","author":"Bourgonje","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1310\/hpj4907-647","article-title":"Dapagliflozin","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp. Pharm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"035","DOI":"10.1055\/s-0044-1785196","article-title":"New nomenclature for nonalcoholic fatty liver disease: understanding metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-and alcohol-associated liver disease, and their implications in clinical practice[C]\/\/Seminars in liver disease","volume":"44","author":"Canivet","year":"2024","journal-title":"Thieme Medical Publishers, Inc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.3390\/nu15224757","article-title":"The role of epigenetic control of mitochondrial (dys) function in MASLD onset and progression","volume":"15","author":"Caputo","year":"2023","journal-title":"Nutrients"},{"key":"B11","volume-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): insights on pathophysiological mechanisms through metabolomics and fluxomics","author":"Carli","year":"2024"},{"key":"B12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obesity Metabolic Syndrome"},{"key":"B13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.tem.2015.07.006","article-title":"Ceramides\u2013lipotoxic inducers of metabolic disorders","volume":"26","author":"Chaurasia","year":"2015","journal-title":"Trends Endocrinol. Metabolism"},{"key":"B14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/biom15070990","article-title":"Metabolic dysfunction-associated steatotic liver disease: from a very low-density lipoprotein perspective","volume":"15","author":"Chen","year":"2025","journal-title":"Biomolecules"},{"key":"B15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.47852\/bonviewmedin52024744","article-title":"An ensemble approach for artificial neural network-based liver disease identification from optimal features through hybrid modeling integrated with advanced explainable AI","volume":"2","author":"Chowdhury","year":"2025","journal-title":"Medinformatics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12130","DOI":"10.3390\/ijms262412130","article-title":"The influence of glucagon-like peptide-1 receptor agonists and other incretin hormone agonists on body composition","volume":"26","author":"Chrysavgis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/livers2040023","article-title":"Role of oxidative stress in liver disorders","volume":"2","author":"Conde de la Rosa","year":"2022","journal-title":"Livers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/14737159.2025.2534962","article-title":"Regulation of biomarker analysis: what can be translated in the clinic?","volume":"25","author":"Diamantopoulos","year":"2025","journal-title":"Expert Rev. Mol. Diagnostics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/vhrm.s12187397","article-title":"A review of pioglitazone hcl and glimepiride in the treatment of type 2 diabetes","volume":"3","author":"Dorkhan","year":"2007","journal-title":"Vasc. Health Risk Management"},{"key":"B22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.eprac.2024.04.016","article-title":"Role of resmetirom, a liver-directed, thyroid hormone receptor beta-selective agonist, in managing nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"30","author":"Dutta","year":"2024","journal-title":"Endocr. Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","year":"2024","journal-title":"Obes. Facts"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e19779","DOI":"10.7717\/peerj.19779","article-title":"Serum \u03b2-klotho is a potential biomarker for diagnosing alcoholic liver disease and differentiating from nonalcoholic fatty liver disease","volume":"13","author":"Fang","year":"2025","journal-title":"PeerJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.14218\/JCTH.2024.00019","article-title":"Mechanism of metabolic dysfunction-associated steatotic liver disease: important role of lipid metabolism","volume":"12","author":"Feng","year":"2024","journal-title":"J. Clinical Translational Hepatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1042\/BCJ20210071","article-title":"SREBP-1c and lipogenesis in the liver: an update","volume":"478","author":"Ferr\u00e9","year":"2021","journal-title":"Biochem. Journal"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101303","DOI":"10.1016\/j.plipres.2024.101303","article-title":"Lipid sensing by PPAR\u03b1: role in controlling hepatocyte gene regulatory networks and the metabolic response to fasting","volume":"96","author":"Fougerat","year":"2024","journal-title":"Prog. Lipid Research"},{"key":"B28","doi-asserted-by":"publisher","first-page":"934396","DOI":"10.1155\/2012\/934396","article-title":"Non\u2010alcoholic fatty liver disease: the bile acid\u2010activated farnesoid x receptor as an emerging treatment target","volume":"2012","author":"Fuchs","year":"2012","journal-title":"J. Lipids"},{"key":"B29","article-title":"GPNMB contributes to NASH progression with M2 polarization of hepatic macrophages and activation of hepatic stellate cells","volume-title":"The liver meeting 2023","author":"Fukumoto","year":"2023"},{"key":"B30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1101\/2023.10.23.562885","article-title":"Beneficial effects of intermittent fasting in NASH and subsequent HCC development are executed by concerted PPAR\u03b1 and PCK1 action in hepatocytes","author":"Gallage","year":"2023","journal-title":"bioRxiv"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.cmet.2024.04.015","article-title":"A 5: 2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR\u03b1 and PCK1","volume":"36","author":"Gallage","year":"2024","journal-title":"Cell Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13148-018-0525-9","article-title":"Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways","volume":"10","author":"Gerhard","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cytogfr.2018.01.004","article-title":"Adiponectin: a potential therapeutic target for metabolic syndrome","volume":"39","author":"Ghadge","year":"2018","journal-title":"Cytokine Growth Factor Reviews"},{"key":"B34","doi-asserted-by":"publisher","first-page":"eabf8271","DOI":"10.1126\/science.abf8271","article-title":"Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1","volume":"376","author":"Gosis","year":"2022","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2025","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Medicine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-025-01307-5","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume":"22","author":"He","year":"2025","journal-title":"Cell. Molecular Immunology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e240048","DOI":"10.1148\/rg.240048","article-title":"MASLD: what we have learned and where we need to go\u2014a call to action","volume":"44","author":"Hosseini","year":"2024","journal-title":"Radiographics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"113937","DOI":"10.1016\/j.intimp.2024.113937","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice","volume":"147","author":"Hu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1507\/endocrj.ej13-0121","article-title":"Recent progress on the role of ChREBP in glucose and lipid metabolism","volume":"60","author":"Iizuka","year":"2013","journal-title":"Endocr. Journal"},{"key":"B41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/flgastro-2024-102856","article-title":"Role of anti-diabetic medications in the management of MASLD","volume":"16","author":"Isaacs","year":"2025","journal-title":"Frontline Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6148","DOI":"10.3390\/jcm14176148","article-title":"Is there a diagnostic miracle on the horizon? emerging biomarkers in MASLD","volume":"14","author":"Iwaszko-Sochal","year":"2025","journal-title":"J. Clinical Medicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/MEG.0b013e328317f4b5","article-title":"Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels","volume":"21","author":"Jiang","year":"2009","journal-title":"Eur. Journal Gastroenterology Hepatology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jhep.2022.04.010","article-title":"Lack of VMP1 impairs hepatic lipoprotein secretion and promotes non-alcoholic steatohepatitis","volume":"77","author":"Jiang","year":"2022","journal-title":"J. Hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cmet.2012.03.005","article-title":"Diacylglycerol activation of protein kinase C\u03b5 and hepatic insulin resistance","volume":"15","author":"Jornayvaz","year":"2012","journal-title":"Cell Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","first-page":"155835","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism-Clinical Exp."},{"key":"B48","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of \u03b2Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1042\/CS20050078","article-title":"Role of resistin in obesity, insulin resistance and type II diabetes","volume":"109","author":"Kusminski","year":"2005","journal-title":"Clin. Science"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI189953","article-title":"Disease classification, diagnostic challenges, and evolving clinical trial design in MASLD","volume":"135","author":"Lauridsen","year":"2025","journal-title":"J. Clinical Investigation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00125-020-05296-0","article-title":"Branched-chain amino acid metabolism, insulin sensitivity and liver fat response to exercise training in sedentary dysglycaemic and normoglycaemic men","volume":"64","author":"Lee","year":"2021","journal-title":"Diabetologia"},{"key":"B52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jgr.2021.10.005","article-title":"Upregulation of adiponectin by Ginsenoside Rb1 contributes to amelioration of hepatic steatosis induced by high fat diet","volume":"46","author":"Li","year":"2022","journal-title":"J. Ginseng Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/biomedicines11123280","article-title":"SREBP regulation of lipid metabolism in liver disease, and therapeutic strategies","volume":"11","author":"Li","year":"2023","journal-title":"Biomedicines"},{"key":"B54","doi-asserted-by":"publisher","first-page":"20420188251321602","DOI":"10.1177\/20420188251321602","article-title":"Clinical and pathological characteristics of metabolic dysfunction-associated steatotic liver disease and the key role of epigenetic regulation: implications for molecular mechanism and treatment","volume":"16","author":"Li","year":"2025","journal-title":"Ther. Adv. Endocrinol. Metabolism"},{"key":"B55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12944-024-02416-2","article-title":"Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics","volume":"24","author":"Liang","year":"2025","journal-title":"Lipids Health Disease"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/biomedicines10061232","article-title":"Effects of thyroid hormones on lipid metabolism pathologies in non-alcoholic fatty liver disease","volume":"10","author":"Liao","year":"2022","journal-title":"Biomedicines"},{"key":"B57","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1194\/jlr.M081836","article-title":"Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice","volume":"59","author":"Linden","year":"2018","journal-title":"J. Lipid Research"},{"key":"B58","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2337\/db23-0357","article-title":"Roles of activin A and gpnmb in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"73","author":"Liu","year":"2024","journal-title":"Diabetes"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12272-025-01574-w","article-title":"Resmetirom, the first FDA-approved drug for MASH: from drug discovery and action mechanisms to clinical trials","volume":"48","author":"Liu","year":"2025","journal-title":"Archives Pharmacal Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1528671","DOI":"10.3389\/fphar.2025.1528671","article-title":"Research advances in traditional Chinese medicine formulae and active components targeting lipid metabolism for hepatocellular carcinoma therapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44319-025-00501-w","article-title":"GPNMB marks a quiescent cell population in melanoma and promotes metastasis formation","volume":"26","author":"Lotti","year":"2025","journal-title":"EMBO Reports"},{"key":"B63","volume-title":"Non-invasive biomarkers for the prediction of disease progression in metabolic associated fatty liver disease","author":"Maier","year":"2021"},{"key":"B64","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s44324-024-00018-1","article-title":"Dysfunctional VLDL metabolism in MASLD","volume":"2","author":"Marigorta","year":"2024","journal-title":"Metabolic Health Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/jcm14020428","article-title":"The triad of risk: linking MASLD, cardiovascular disease and type 2 diabetes; from pathophysiology to treatment","volume":"14","author":"Michalopoulou","year":"2025","journal-title":"J. Clin. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"10795","DOI":"10.3390\/ijms251910795","article-title":"Hepatokines and MASLD: the GLP1-Ras-FGF21-fetuin-A crosstalk as a therapeutic target","volume":"25","author":"Milani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13578-025-01411-z","article-title":"Post-translational modifications in the pathophysiological process of metabolic dysfunction-associated steatotic liver disease","volume":"15","author":"Min","year":"2025","journal-title":"Cell Biosci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/diagnostics15030258","article-title":"Diagnosis and management of acute pancreatitis","volume":"15","author":"Mittal","year":"2025","journal-title":"Diagnostics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s43066-021-00134-3","article-title":"Correlation between adiponectin level and the degree of fibrosis in patients with non-alcoholic fatty liver disease","volume":"11","author":"Mohamed","year":"2021","journal-title":"Egypt. Liver J."},{"key":"B70","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5372\/1905-7415.1002.478","article-title":"Serum microRNA-34a is potential biomarker for inflammation in nonalcoholic fatty liver disease","volume":"10","author":"Muangpaisarn","year":"2016","journal-title":"Asian Biomed."},{"key":"B71","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.dld.2025.01.119","article-title":"Carriage of rare pathogenic apob variants predispose to severe masld and hcc","volume":"57","author":"Mureddu","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"Jama Intern Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway","volume":"187","author":"Nie","year":"2024","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"crossref","first-page":"10600280251322002","DOI":"10.1177\/10600280251322002","article-title":"Therapeutic potential of GLP-1 receptor agonists in metabolic associated steatotic liver disease","volume":"59","author":"Nowak","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1053\/j.gastro.2022.11.019","article-title":"Hepatocyte Kctd17 inhibition ameliorates glucose intolerance and hepatic steatosis caused by obesity-induced Chrebp stabilization","volume":"164","author":"Oh","year":"2023","journal-title":"Gastroenterology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"21268","DOI":"10.1038\/s41598-021-99958-7","article-title":"Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways","volume":"11","author":"Paquette","year":"2021","journal-title":"Sci. Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"100321","DOI":"10.1016\/j.metop.2024.100321","article-title":"Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Pasqualotto","year":"2024","journal-title":"Metab. Open"},{"key":"B79","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.clinsp.2025.100737","article-title":"Long-term pioglitazone use in MASLD patients: insights from a multicentric preliminary study","volume":"80","author":"Pereira","year":"2025","journal-title":"Clinics"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"B81","volume-title":"Study of new strategies for steatotic liver disease: SIRT1-mediated modulation of VLDLR levels and evaluation of a soluble epoxyde hydrolase-targeted PROTAC","author":"Peyman","year":"2024"},{"key":"B82","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.3390\/ijms25115640","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease: from pathogenesis to current therapeutic options","volume":"25","author":"Portincasa","year":"2024","journal-title":"Int. Journal Molecular Sciences"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.tem.2025.03.006","article-title":"Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Priego-Parra","year":"2025","journal-title":"Trends Endocrinol. Metabolism"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e42189","DOI":"10.1097\/MD.0000000000042189","article-title":"Efficacy of traditional Chinese medicine-based clearing heat and laxative method against nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"104","author":"Qu","year":"2025","journal-title":"Medicine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.2174\/0109298673322846240724063112","article-title":"Mitochondrial dysfunction in MASLD: unveiling mechanisms and optimizing therapeutic strategies","volume":"32","author":"Radosavljevi\u0107","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"B86","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1097\/MS9.0000000000002195","article-title":"Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis","volume":"86","author":"Raja","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"B87","doi-asserted-by":"publisher","first-page":"108932","DOI":"10.1016\/j.jdiacomp.2024.108932","article-title":"The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"39","author":"Ren","year":"2025","journal-title":"J. Diabetes Its Complicat."},{"key":"B88","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J. Lipid Research"},{"key":"B89","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1327814","DOI":"10.3389\/fnut.2023.1327814","article-title":"Metformin: update on mechanisms of action on liver diseases","volume":"10","author":"Ruan","year":"2023","journal-title":"Front. Nutrition"},{"key":"B91","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev."},{"key":"B92","article-title":"Triple hormone receptor agonist retatrutide resolves steatosis in> 85% of subjects with MASLD and obesity in association with improved metabolic health","volume-title":"The liver meeting 2023","author":"Sanyal","year":"2023"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Medicine"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/antiox13111386","article-title":"Gut microbiota and metabolic dysfunction-associated steatotic liver disease","volume":"13","author":"Scarpellini","year":"2024","journal-title":"Antioxidants"},{"key":"B95","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/1744666X.2023.2294046","article-title":"The pathophysiology of MASLD: an immunometabolic perspective","volume":"20","author":"Schw\u00e4rzler","year":"2024","journal-title":"Expert Review Clinical Immunology"},{"key":"B96","first-page":"369","article-title":"Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores","volume":"103","author":"Senate\u015f","year":"2012","journal-title":"Minerva Medica"},{"key":"B97","doi-asserted-by":"publisher","first-page":"10456","DOI":"10.3389\/ebm.2025.10456","article-title":"Vitamin D3 affects liver expression of pro-\/anti-inflammatory cytokines and nitric oxide synthases in type 2 diabetes","volume":"250","author":"Shymanskyi","year":"2025","journal-title":"Exp. Biol. Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1056\/NEJMe2504717","article-title":"Semaglutide for metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Simon","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.3748\/wjg.v30.i48.5205","article-title":"GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: novel therapeutic agents for metabolic dysfunction-associated steatohepatitis","volume":"30","author":"Singh","year":"2024","journal-title":"World J. Gastroenterology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/oby.24360","article-title":"Efficacy and safety of GLP\u20101 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: a bayesian NMA","volume":"33","author":"Sinha","year":"2025","journal-title":"Obesity"},{"key":"B101","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/biomedicines10030524","article-title":"The role of gut\u2013liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC","volume":"10","author":"Song","year":"2022","journal-title":"Biomedicines"},{"key":"B102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/metabo14010012","article-title":"Lipid metabolism in metabolic-associated steatotic liver disease (MASLD)","volume":"14","author":"Syed-Abdul","year":"2023","journal-title":"Metabolites"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e70532","DOI":"10.1002\/mco2.70532","article-title":"Alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease: molecular pathogenesis and therapeutic interventions","volume":"6","author":"Tan","year":"2025","journal-title":"MedComm"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/biom15081178","article-title":"Targeting lactylation: from metabolic reprogramming to precision therapeutics in liver diseases","volume":"15","author":"Tan","year":"2025","journal-title":"Biomolecules"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1476419","DOI":"10.3389\/fmed.2024.1476419","article-title":"Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice","volume":"11","author":"Tao","year":"2024","journal-title":"Front. Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S2213-8587(22)00074-2","article-title":"Tirzepatide adds hepatoprotection to its armoury","volume":"10","author":"Targher","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"109953","DOI":"10.1016\/j.cbi.2022.109953","article-title":"Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: role of TLR4\/TGF-\u03b21 axis","volume":"361","author":"Tawfiq","year":"2022","journal-title":"Chemico-Biological Interact."},{"key":"B108","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/metabo12060514","article-title":"Interactions between tryptophan metabolism, the gut microbiome and the immune system as potential drivers of non-alcoholic fatty liver disease (NAFLD) and metabolic diseases","volume":"12","author":"Teunis","year":"2022","journal-title":"Metabolites"},{"key":"B109","volume-title":"The new epigenetic driver role of PPAR\u03b1 and mitochondria in metabolic dysfunction associated liver disease (MASLD), paving the way towards new therapeutics and diagnostic biomarkers","author":"Theys","year":"2024"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1283170","DOI":"10.3389\/fmmed.2023.1283170","article-title":"Loss of PPAR\u03b1 function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated steatotic liver disease (MASLD)","volume":"3","author":"Theys","year":"2024","journal-title":"Front. Molecular Medicine"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.5114\/aoms\/161228","article-title":"Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus","volume":"20","author":"Tian","year":"2023","journal-title":"Archives Med. Sci. AMS"},{"key":"B112","doi-asserted-by":"publisher","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front. Endocrinology"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13105-024-01037-8","article-title":"Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for metabolic dysfunction-associated steatotic liver disease assessment","volume":"81","author":"Tobaruela-Resola","year":"2024","journal-title":"J. Physiology Biochemistry"},{"key":"B114","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s13105-025-01110-w","article-title":"The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD","volume":"81","author":"Tobaruela-Resola","year":"2025","journal-title":"J. Physiology Biochem."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e35488","DOI":"10.1097\/MD.0000000000035488","article-title":"Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: a meta-analysis and trials sequential analysis","volume":"102","author":"Tong","year":"2023","journal-title":"Medicine"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e13909","DOI":"10.1111\/eci.13909","article-title":"Systematic review with meta\u2010analysis: branched\u2010chain amino acid supplementation in liver disease","volume":"53","author":"Van Dijk","year":"2023","journal-title":"Eur. Journal Clinical Investigation"},{"key":"B117","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1210\/jc.2016-3237","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J. Clinical Endocrinology Metabolism"},{"key":"B118","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/bph.14095","article-title":"Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non\u2010alcoholic fatty liver disease","volume":"175","author":"Wang","year":"2018","journal-title":"Br. Journal Pharmacology"},{"key":"B119","doi-asserted-by":"publisher","first-page":"803037","DOI":"10.3389\/fimmu.2021.803037","article-title":"Macrophage polarization and its role in liver disease","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"B121","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.3390\/ijms26094077","article-title":"Targeting metabolism: innovative therapies for MASLD unveiled","volume":"26","author":"Wang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tem.2025.04.009","article-title":"TREM2-expressing macrophages in liver diseases","volume":"37","author":"Wang","year":"2025","journal-title":"Trends Endocrinol. Metabolism"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1210\/clinem\/dgaf336","article-title":"Efficacy of GLP-1-based therapies on metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis","volume":"110","author":"Wang","year":"2025","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1008132","DOI":"10.37349\/eds.2025.1008132","article-title":"Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective","volume":"3","author":"Weiskirchen","year":"2025","journal-title":"Explor. Drug Sci."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1601633","DOI":"10.3389\/fendo.2025.1601633","article-title":"SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Endocrinol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"7459","DOI":"10.1038\/s41467-025-62891-8","article-title":"A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD","volume":"16","author":"Wu","year":"2025","journal-title":"Nat. Commun."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cpt.3606","article-title":"Insights into clinical trials for drugs targeting MASLD: progress, challenges, and future directions","volume":"117","author":"Wu","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2013.12.003","article-title":"Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice","volume":"60","author":"Xiong","year":"2014","journal-title":"J. Hepatology"},{"key":"B129","doi-asserted-by":"publisher","first-page":"889858","DOI":"10.3389\/fendo.2022.889858","article-title":"LncRNA GAS5 knockdown mitigates hepatic lipid accumulation via regulating MiR-26a-5p\/PDE4B to activate cAMP\/CREB pathway","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"100038","DOI":"10.1016\/j.intonc.2026.100038","article-title":"Harnessing computational power for intelligent oncology in the age of large models: status, challenges, and prospects","volume":"2","author":"Xu","year":"2026","journal-title":"Intell. Oncology"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1097\/CM9.0000000000003629","article-title":"MASLD development: from molecular pathogenesis toward therapeutic strategies","volume":"138","author":"Yang","year":"2025","journal-title":"Chin. Medical Journal"},{"key":"B132","doi-asserted-by":"publisher","first-page":"101168","DOI":"10.1016\/j.bbrep.2021.101168","article-title":"Metformin treatment reverses high fat diet-induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways","volume":"28","author":"Yasmin","year":"2021","journal-title":"Biochem. Biophysics Rep."},{"key":"B133","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1126\/sciadv.adx2681","article-title":"Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH","volume":"11","author":"Yu","year":"2010","journal-title":"Sci. Adv."},{"key":"B134","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3390\/nu16183061","article-title":"Biomarkers for health functional foods in metabolic dysfunction-associated steatotic liver disorder (MASLD) prevention: an integrative analysis of network pharmacology, gut microbiota, and multi-omics","volume":"16","author":"Yuan","year":"2024","journal-title":"Nutrients"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/apt.70196","article-title":"GLP\u20101 receptor agonists and Glucagon\/GIP\/GLP\u20101 receptor dual or triple agonists\u2014mechanism of action and emerging therapeutic landscape in MASLD","volume":"61","author":"Zafer","year":"2025","journal-title":"Alimentary Pharmacol. Ther"},{"key":"B136","doi-asserted-by":"publisher","first-page":"9010","DOI":"10.3390\/ijms26189010","article-title":"The combination empagliflozin\/metformin attenuates the progression of metabolic dysfunction-associated steatotic liver disease in a diet-induced experimental rat model","volume":"26","author":"Zambrano-V\u00e1squez","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B137","doi-asserted-by":"publisher","first-page":"e1219","DOI":"10.20883\/medical.e1219","article-title":"Semaglutide as a promising treatment for metabolic dysfunction-associated steatotic liver disease","volume":"94","author":"Zasadzi\u0144ska","year":"2025","journal-title":"J. Med. Sci."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10620-025-09464-3","article-title":"The emerging therapeutic promise of SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease","volume":"71","author":"Zhang","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"B139","doi-asserted-by":"publisher","first-page":"110515","DOI":"10.4239\/wjd.v16.i9.110515","article-title":"Macrophage and inflammation in diabetes and metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutic strategies","volume":"16","author":"Zhang","year":"2025","journal-title":"World J. Diabetes"},{"key":"B140","doi-asserted-by":"publisher","first-page":"309","DOI":"10.47852\/bonviewmedin52025080","article-title":"HBV integration into host superenhancers might not be a risk factor for hepatocellular carcinoma","volume":"2","author":"Zhang","year":"2025","journal-title":"Medinformatics"},{"key":"B141","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1038\/s41467-023-41061-8","article-title":"Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPAR\u03b1 nucleus-cytoplasm shuttling","volume":"14","author":"Zhong","year":"2023","journal-title":"Nat. Communications"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/hep.26167","article-title":"Resistin reduces mitochondria and induces hepatic steatosis in mice by the protein kinase C\/protein kinase G\/p65\/PPAR gamma coactivator 1 alpha pathway","volume":"57","author":"Zhou","year":"2013","journal-title":"Hepatology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"7293","DOI":"10.2147\/DDDT.S524893","article-title":"Therapeutic targeting of PPAR\u03b3 in nonalcoholic fatty liver disease: efficacy, safety, and drug development","volume":"19","author":"Zhou","year":"2025","journal-title":"Drug Des. Dev. Ther."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1808135\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:36:10Z","timestamp":1776922570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1808135\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":143,"alternative-id":["10.3389\/fcell.2026.1808135"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1808135","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"article-number":"1808135"}}